Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

Last updated: May 22, 2024
Sponsor: Novartis Pharmaceuticals
Overall Status: Active - Recruiting

Phase

N/A

Condition

Red Blood Cell Disorders

Sickle Cell Disease

Treatment

OTQ923

Clinical Study ID

NCT06155500
CADPT03A12001
  • Ages > 18
  • All Genders

Study Summary

CADPT03A12001 is a prospective, multi-center study that is designed to follow all enrolled patients who have received treatment with OTQ923 for long-term safety and efficacy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Accepted invitation to join based on prior treatment with gene therapy.

  2. Patients must provide informed consent prior to their entry into this study.

Exclusion

Exclusion Criteria:

  1. Completion of less than 1 year of safety follow-up in the treatment protocol (CADPT03A12101)

Study Design

Total Participants: 5
Treatment Group(s): 1
Primary Treatment: OTQ923
Phase:
Study Start date:
April 16, 2024
Estimated Completion Date:
January 11, 2039

Study Description

This study is monitoring patients treated with OTQ923, an investigational drug product of ex vivo genome-edited autologous hematopoietic stem and progenitor cells (HSPCs) that induces fetal hemoglobin (HbF) production, for a total of 15 years following infusion to monitor long-term safety and efficacy.

Connect with a study center

  • St Jude Childrens Rsrch Hospital

    Memphis, Tennessee 38105-3678
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.